(Total Views: 767)
Posted On: 10/22/2024 7:13:52 PM
Post# of 147996
Kat, you said: " But ViiV Got its hands on dolutegravir Which made it an immediate and valid threat to G regarding HIV."
Fallback to 2011:
Antiviral activity, safety, and pharmacokinetics, /pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
" Dolutegravir (DTG), discovered by a Shionogi and GlaxoSmithKline research collaboration "
Authors
Sherene Min 1, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy, Ivy Song, Richard Stroder, Shuguang Chen, Mark Underwood, Tamio Fujiwara, Stephen Piscitelli, --- ** Jay Lalezari **
Affiliation:
GlaxoSmithKline,
Research Triangle Park, North Carolina 27709, USA. sherene.s.min@gsk.com
https://pubmed.ncbi.nlm.nih.gov/21716073/
https://journals.lww.com/aidsonline/fulltext/...and.7.aspx
___
More deep-rooted Dr. J connections.
Sure are alot of significant past collaborations.
Also realized 1 thing about these past trials, collaborators, grants, etc.,
None, that I've seen at least, are Gilead controlled or funded & etc..
Learned from here & other boards Gilead is the not so good company.
Tell ya what, if these past connects to ViiV/GSK/Pfizer, have carried forward into 2024 & forward, Gilead is going to be in serious trouble.
My bet is ViiV does not take the headline on a Cytodyn deal of indications.
With what LL brings to the table, GSK will directly partner with Cytodyn.
The deal structure will be outstanding & LL drug development outside of HIV, will of course too skyrocket.
Fallback to 2011:
Antiviral activity, safety, and pharmacokinetics, /pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
" Dolutegravir (DTG), discovered by a Shionogi and GlaxoSmithKline research collaboration "
Authors
Sherene Min 1, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy, Ivy Song, Richard Stroder, Shuguang Chen, Mark Underwood, Tamio Fujiwara, Stephen Piscitelli, --- ** Jay Lalezari **
Affiliation:
GlaxoSmithKline,
Research Triangle Park, North Carolina 27709, USA. sherene.s.min@gsk.com
https://pubmed.ncbi.nlm.nih.gov/21716073/
https://journals.lww.com/aidsonline/fulltext/...and.7.aspx
___
More deep-rooted Dr. J connections.
Sure are alot of significant past collaborations.
Also realized 1 thing about these past trials, collaborators, grants, etc.,
None, that I've seen at least, are Gilead controlled or funded & etc..
Learned from here & other boards Gilead is the not so good company.
Tell ya what, if these past connects to ViiV/GSK/Pfizer, have carried forward into 2024 & forward, Gilead is going to be in serious trouble.
My bet is ViiV does not take the headline on a Cytodyn deal of indications.
With what LL brings to the table, GSK will directly partner with Cytodyn.
The deal structure will be outstanding & LL drug development outside of HIV, will of course too skyrocket.
(4)
(0)Scroll down for more posts ▼
